{
"id":"mk19_bb_np_s13",
"subspecialtyId":"np",
"title":"Hypertension",
"jsonContent":{
"type":"section",
"id":"mk19_bb_np_s13",
"title":{
"__html":"Hypertension"
},
"titleNode":{
"type":"section-title",
"hlId":"01da3e",
"children":[
"Hypertension"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_np_s13_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"ae0d22",
"children":[
" ",
{
"type":"alert",
"children":[
"Before labeling a person as having hypertension, use an average ",
{
"type":"abbreviation",
"title":"blood pressure",
"children":[
"BP"
]
},
" based on two or more readings obtained on two or more occasions. Out-of-office ",
{
"type":"abbreviation",
"title":"ambulatory blood pressure monitoring",
"children":[
"ABPM"
]
},
" and ",
{
"type":"abbreviation",
"title":"home blood pressure measurement",
"children":[
"HBPM"
]
},
" are recommended to confirm the diagnosis of hypertension and for titration of BP-lowering medication."
]
},
" "
]
},
{
"type":"p",
"hlId":"c65f89",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"White coat hypertension."
]
},
" In adults with an untreated ",
{
"type":"abbreviation",
"title":"systolic blood pressure",
"children":[
"SBP"
]
},
" >130 but <160 mm Hg or ",
{
"type":"abbreviation",
"title":"diastolic blood pressure",
"children":[
"DBP"
]
},
" >80 but <100 mm Hg, it is reasonable to evaluate for the presence of white coat hypertension using either daytime ABPM or HBPM before diagnosis of hypertension."
]
},
{
"type":"p",
"hlId":"eb69d2",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Masked hypertension."
]
},
" Masked hypertension is defined as elevated BP detected by ABPM or HBPM but with a normal office BP measurement. In adults with elevated office BP (120-129/<80 mm Hg) but not meeting the criteria for hypertension, evaluating for masked hypertension with daytime ABPM or HBPM is reasonable."
]
},
{
"type":"p",
"hlId":"2ca72a",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Target BP for older adult patients."
]
},
" The ",
{
"type":"abbreviation",
"title":"American College of Cardiology",
"children":[
"ACC"
]
},
"/",
{
"type":"abbreviation",
"title":"American Heart Association",
"children":[
"AHA"
]
},
" target SBP for noninstitutionalized, ambulatory, community-dwelling patients aged ≥65 years is <130 mm Hg. The ",
{
"type":"abbreviation",
"title":"American College of Physicians",
"children":[
"ACP"
]
},
" guideline recommends a target SBP <150 mm Hg in patients aged ≥60 years."
]
},
{
"type":"p",
"hlId":"8149cd",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Target BP for patients with selected comorbidities."
]
},
" The ACC/AHA recommends a target BP <130/80 mm Hg for all patients with comorbidities, including all forms of ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"atherosclerotic cardiovascular disease",
"children":[
"ASCVD"
]
},
","
]
},
" ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"heart failure",
"children":[
"HF"
]
},
","
]
},
" ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"chronic kidney disease",
"children":[
"CKD"
]
},
","
]
},
" and diabetes. The ",
{
"type":"abbreviation",
"title":"American Diabetes Association",
"children":[
"ADA"
]
},
" recommends a target BP <140/80 mm Hg for patients with diabetes; a target BP <130/80 mm Hg may be considered if 10-year ASCVD risk is ≥15%. ACP guidelines indicate a target SBP <140 mm Hg may be reasonable in some patients aged ≥60 years at high cardiovascular risk or with a history of stroke or ",
{
"type":"abbreviation",
"title":"transient ischemic attack",
"children":[
"TIA"
]
},
" based on individualized assessment."
]
},
{
"type":"p",
"hlId":"ab9cf7",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Secondary hypertension."
]
},
" Most patients with established hypertension have primary hypertension. Consider secondary hypertension in patients who have atypical clinical features (early onset, absent family history, hypokalemia, evidence of kidney disease) or have resistant hypertension (not at target goal despite the use of three antihypertensive agents, including a diuretic)."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_np_s13_inline_t1"
],
"forceOpen":true
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"11c94f",
"children":[
"Do not use plasma renin activity to risk stratify patients with hypertension or to predict response to specific drugs."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s13_2",
"title":{
"__html":"Test Yourself"
},
"titleNode":{
"type":"section-title",
"hlId":"7866cc",
"children":[
"Test Yourself"
]
},
"children":[
{
"type":"p",
"hlId":"3657e0",
"class":"test",
"children":[
"A 35-year-old woman is evaluated for persistent fatigue and resistant hypertension. Serum potassium level is 3.3 mEq/L."
]
},
{
"type":"p",
"hlId":"b4858c",
"class":"test_answer",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Answer:"
]
},
" ",
"For diagnosis, choose primary aldosteronism. For management, select measurement of plasma aldosterone–plasma renin activity ratio."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s13_3",
"title":{
"__html":"Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"fa6a5a",
"children":[
"Testing"
]
},
"children":[
{
"type":"p",
"hlId":"e05fc9",
"children":[
"Collect data on cardiovascular risk factors and possible underlying secondary causes. Initial evaluation includes:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"df335a",
"children":[
"laboratory testing for kidney function, fasting blood glucose, fasting lipid panel, serum potassium, and serum calcium"
]
},
" ",
{
"type":"list-item",
"hlId":"d15f88",
"children":[
" ",
{
"type":"abbreviation",
"title":"electrocardiogram",
"children":[
"ECG"
]
},
" "
]
},
" ",
{
"type":"list-item",
"hlId":"82f881",
"children":[
"urinalysis and albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s13_4",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_bb_np_s13_inline_t2"
],
"forceOpen":true
},
{
"type":"p",
"hlId":"8aa977",
"children":[
"First-line antihypertensive agents are those shown to reduce clinical events."
]
},
{
"type":"p",
"hlId":"cb848c",
"children":[
"For hypertension in the non-Black population (see below), older adults, and patients with diabetes without albuminuria:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"220e52",
"children":[
"thiazide diuretic"
]
},
" ",
{
"type":"list-item",
"hlId":"effae2",
"children":[
" ",
{
"type":"abbreviation",
"title":"calcium channel blocker",
"children":[
"CCB"
]
},
" "
]
},
" ",
{
"type":"list-item",
"hlId":"b77d4c",
"children":[
{
"type":"abbreviation",
"title":"angiotensin-converting enzyme",
"children":[
"ACE"
]
},
" inhibitor or ",
{
"type":"abbreviation",
"title":"angiotensin receptor blocker",
"children":[
"ARB"
]
}
]
},
" "
]
},
{
"type":"p",
"hlId":"d1ab1a",
"children":[
"For patients with diabetes and albuminuria:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"b77d4c",
"children":[
"ACE inhibitor or ARB"
]
},
" "
]
},
{
"type":"p",
"hlId":"ac9b52",
"children":[
"For patients with stage G1 kidney disease or higher with proteinuric kidney disease:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"b77d4c",
"children":[
"ACE inhibitor or ARB"
]
},
" "
]
},
{
"type":"p",
"hlId":"95888a",
"children":[
"For stage 1 hypertension in the Black population (see below) without CKD or HF and with or without diabetes (but no albuminuria):"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"220e52",
"children":[
"thiazide diuretic"
]
},
" ",
{
"type":"list-item",
"hlId":"a85eda",
"children":[
"CCB"
]
},
" "
]
},
{
"type":"p",
"hlId":"36d073",
"children":[
"For patients with stage 2 hypertension:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"3410a6",
"children":[
"combination of two first-line antihypertensive drugs of different classes (except ACE inhibitors and ARBs)"
]
},
" "
]
},
{
"type":"p",
"hlId":"adac57",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Explanation of race:"
]
},
" Current guidelines recommend that initial antihypertensive therapy should include a thiazide diuretic or a CCB in Black persons; however, physicians are increasingly aware of the limitations in making management decisions based on skin color and that labeling patients as Black or not Black may be overly simplistic and inappropriate. Without more precise variables to explain differences in response to therapy among patients, many experts and guidelines continue to use race-based terminology, although guidelines addressing race-based recommendations are evolving."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"4573f5",
"children":[
"Choose a loop diuretic rather than a thiazide diuretic for patients with ",
{
"type":"abbreviation",
"title":"glomerular filtration rate",
"children":[
"GFR"
]
},
" <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s13_5",
"title":{
"__html":"Renovascular Hypertension"
},
"titleNode":{
"type":"section-title",
"hlId":"81171b",
"children":[
"Renovascular Hypertension"
]
},
"children":[
{
"type":"p",
"hlId":"2756ba",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Testing"
]
},
" "
]
},
{
"type":"p",
"hlId":"293f5b",
"children":[
" ",
{
"type":"alert",
"children":[
"Routine testing for renovascular disease in older patients with ASCVD is not recommended."
]
},
" "
]
},
{
"type":"p",
"hlId":"42f478",
"children":[
"In young women with resistant hypertension and a high clinical suspicion for fibromuscular dysplasia, renal artery imaging may be considered:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"b50890",
"children":[
"renal duplex Doppler ultrasonography"
]
},
" ",
{
"type":"list-item",
"hlId":"9922ef",
"children":[
{
"type":"abbreviation",
"title":"magnetic resonance angiography",
"children":[
"MRA"
]
},
" or ",
{
"type":"abbreviation",
"title":"computed tomography angiography",
"children":[
"CTA"
]
},
" (most accurate, but avoid in severe CKD)"
]
},
" "
]
},
{
"type":"p",
"hlId":"afcd3e",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Treatment"
]
},
" "
]
},
{
"type":"p",
"hlId":"640ac3",
"children":[
"Renal artery angioplasty is no better than medical therapy in patients with atherosclerotic renovascular disease and stable kidney function. Therapy is directed at controlling ASCVD risk factors."
]
},
{
"type":"p",
"hlId":"bced23",
"children":[
" ",
{
"type":"alert",
"children":[
"In young persons with fibromuscular dysplasia, angioplasty may improve BP and cure hypertension."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s13_6",
"title":{
"__html":"Hypertensive Urgency"
},
"titleNode":{
"type":"section-title",
"hlId":"6b1926",
"children":[
"Hypertensive Urgency"
]
},
"children":[
{
"type":"p",
"hlId":"714353",
"children":[
"The treatment of hypertensive urgency (BP >180/120 mm Hg in the absence of symptoms or progressive target-organ damage) differs if the patient has previously treated hypertension or untreated hypertension."
]
},
{
"type":"p",
"hlId":"c19abf",
"children":[
" ",
{
"type":"alert",
"children":[
"Systolic BP should be lowered no more than 25% within the first hour, then to <160/100 mm Hg within the next 2 to 6 hours, then cautiously to target during the following 24 to 48 hours."
]
},
" "
]
},
{
"type":"p",
"hlId":"a704e4",
"children":[
"In patients with preexisting treated hypertension:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"ecc456",
"children":[
"slowly restart the medication(s) in nonadherent patients."
]
},
" ",
{
"type":"list-item",
"hlId":"34cb08",
"children":[
"in adherent patients, either increase the dose of the medication(s) or add an additional agent."
]
},
" "
]
},
{
"type":"p",
"hlId":"3168bf",
"children":[
"In patients with previously untreated hypertension:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"5e4eda",
"children":[
"consider oral furosemide or small doses of clonidine or captopril and observe for several hours for a BP drop of 20 to 30 mm Hg (not to normal BP)."
]
},
" ",
{
"type":"list-item",
"hlId":"6468e1",
"children":[
"begin a long-acting agent; discharge home with follow-up in 2 to 3 days."
]
},
" "
]
}
]
}
]
},
"tablesContent":{
"mk19_bb_np_s13_inline_t1":{
"id":"mk19_bb_np_s13_inline_t1",
"number":1,
"bookId":"np",
"title":{
"__html":"Study Table: Selected Secondary Causes of Hypertension"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"1565c2",
"children":[
"Study Table: Selected Secondary Causes of Hypertension"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e2941",
"class":"col hd l",
"children":[
"Condition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93705d",
"class":"cell txt l",
"children":[
"Drug induced"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"700bf0",
"class":"cell txt l",
"children":[
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"nonsteroidal anti-inflammatory drugs",
"children":[
"NSAIDs"
]
},
","
]
},
" amphetamines/cocaine, sympathomimetics, oral contraceptives, glucocorticoids"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"912e2c",
"class":"cell txt l",
"children":[
"CKD"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1fa18a",
"class":"cell txt l",
"children":[
"Elevated ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"blood urea nitrogen",
"children":[
"BUN"
]
},
","
]
},
" serum creatinine, and potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7523fe",
"class":"cell txt l",
"children":[
"Renovascular disease (atherosclerotic and fibromuscular)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af25b0",
"class":"cell txt l",
"children":[
"Onset of hypertension at young age, especially in women (fibromuscular); atherosclerotic disease often associated with cigarette smoking, flash pulmonary edema, ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"coronary artery disease",
"children":[
"CAD"
]
},
","
]
},
" flank bruits, advanced retinopathy, increased creatinine (usually with bilateral renovascular disease), and increased creatinine after treatment with an ACE inhibitor or ARB"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80d1a5",
"class":"cell txt l",
"children":[
"Primary hyperaldosteronism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"223492",
"class":"cell txt l",
"children":[
"Muscle cramping, nocturia, thirst; physical examination normal; hypokalemia (50%) and elevated plasma aldosterone–plasma renin activity ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"55f15a",
"class":"cell txt l",
"children":[
"Cushing syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"155a7c",
"class":"cell txt l",
"children":[
"Weight gain, menstrual irregularity, hirsutism; truncal obesity, abdominal striae; hypokalemia, metabolic alkalosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43d333",
"class":"cell txt l",
"children":[
"Pheochromocytoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab7bed",
"class":"cell txt l",
"children":[
"Sweating, pounding headache; pallor; tachycardia; hypertension may be episodic with intervals of normal ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"blood pressure",
"children":[
"BP"
]
},
";"
]
},
" increased urine or plasma catecholamines or metanephrine"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_bb_np_s13_inline_t2":{
"id":"mk19_bb_np_s13_inline_t2",
"number":2,
"bookId":"np",
"title":{
"__html":"Study Table: ACC/AHA Classification and Treatment of Blood Pressure "
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"b33bca",
"children":[
"Study Table: ACC/AHA Classification and Treatment of Blood Pressure "
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"883dc7",
"class":"col hd l",
"children":[
"BP Category"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27b282",
"class":"col hd l",
"children":[
"Office-Based Readings (mm Hg)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c4ac0",
"class":"col hd l",
"children":[
"Treatment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff20a8",
"class":"col hd l",
"children":[
"BP Target (mm Hg)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"960b44",
"class":"cell txt l",
"children":[
"Normal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2d4fa",
"class":"cell txt l",
"children":[
"SBP <120 and DBP <80"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d4cd0d",
"class":"cell txt l",
"children":[
"NA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d4cd0d",
"class":"cell txt l",
"children":[
"NA"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2dfe2a",
"class":"cell txt l",
"children":[
"Elevated ",
{
"type":"abbreviation",
"title":"blood pressure",
"children":[
"BP"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a4262",
"class":"cell txt l",
"children":[
"SBP 120-129 and DBP <80"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3fed11",
"class":"cell txt l",
"children":[
"Nonpharmacologic therapy (",
{
"type":"abbreviation",
"title":"nonpharmacologic therapy",
"children":[
"NPT"
]
},
")"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2d4fa",
"class":"cell txt l",
"children":[
"SBP <120 and DBP <80"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"207164",
"class":"cell txt l",
"children":[
"Hypertension, stage 1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5996c1",
"class":"cell txt l",
"children":[
"SBP 130-139 or DBP 80-89"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9ff812",
"class":"cell txt l",
"children":[
"NPT if 10-year ASCVD risk <10%"
]
},
" ",
{
"type":"p",
"hlId":"6cc172",
"class":"cell txt l",
"children":[
"NPT + first-line drugs if clinical ",
{
"type":"abbreviation",
"title":"cardiovascular",
"children":[
"CV"
]
},
" disease or 10-year ASCVD risk ≥10%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"075072",
"class":"cell txt l",
"children":[
"<130/80"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"518611",
"class":"cell txt l",
"children":[
"Hypertension, stage 2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14fe06",
"class":"cell txt l",
"children":[
"SBP ≥140 or DBP ≥90"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb9b2e",
"class":"cell txt l",
"children":[
"Two first-line drugs of different classes, preferably with once-daily dosing, if BP 20/10 mm Hg above target"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"075072",
"class":"cell txt l",
"children":[
"<130/80"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}